AI stocks undercut markets worldwide as oil climbs to its highest price since May - BNN Bloomberg

Canada holds a competitive advantage in Asian LNG markets, benefiting from shorter shipping routes, abundant natural gas, and lower-emission projects. Canada is set to reach 33 million tonnes of annual LNG export capacity by 2030, following LNG Canada's Phase 2 expansion and the addition of Cedar LNG and Woodfibre.

AtlanticNova ScotiaNew BrunswickPrince Edward Island Newfoundland and LabradorCalgaryLethbridgeKitchenerGuelphNorthern OntarioSudburyNorth BaySault Ste. MarieTimminsOttawaKingstonBrockvillePembrokeReginaYorktonSaskatoonPrince AlbertTorontoWatchWeatherPeelHamiltonDurhamYorkHaltonNiagaraQueen's ParkToronto City HallIn PicturesVancouverVancouver IslandCanadaLocal SpotlightRoyal FamilyPoliticsNanosPower PlayQuestion PeriodFederal Election 2025WorldMideast ConflictRussia-Ukraine WarWatchLatestCaptured on CameraPoliticsLifestyleConsumerHealthExplainedEntertainmentTechnologyDeception DecodedAutosEnvironmentBusinessInflationReal EstateAutos

A south London mall that recently welcomed Ikea is preparing for the arrival of even more businesses, a new hotel, and a rejigged bus bay to support bus rapid transit. Iyman Meddoui, president of Westdell Development Corporation, speaks during an announcement at White Oaks Mall in London on Thursday, Oct. 22, 2026. (Geoff Robins/The London Free Press)

The tailored mRNA vaccine is intismeran (or mRNA-4157), which uses a synthetic mRNA that holds the unique genetic coding for up to 34 mutations in a patient’s own cancer cells. To produce the personalized vaccines, researchers compare the genetic sequences of a patient’s cancer cells with those of healthy cells and pick out cancer-specific mutations that could help the immune response selectively target just the cancer cells. In the trial, researchers assessed “recurrence-free survival” or RFS, which is the amount of time a patient has without the cancer returning, and “distant metastasis-free survival” or DMFS, which is the amount of time a patient has without the cancer returning and occurring in a different part of the body than where it began.